Toripalimab

China's NMPA has approved Junshi Biosciences' IND application for JS212, a first-in-class bispecific antibody-drug conjugate simultaneously targeting EGFR and HER3 in various tumor types.

Antengene will present data from four preclinical studies at AACR 2025, featuring novel T-cell engagers and a synthetic lethality approach targeting MTAPnull cancers.

Coherus BioSciences has completed the divestiture of its UDENYCA pegfilgrastim franchise to Intas Pharmaceuticals in a deal valued at up to $558.4 million, receiving $483.4 million upfront with potential for $75 million in milestone payments.

Coherus BioSciences' selective anti-CCR8 antibody CHS-114 demonstrated clinical efficacy in combination with toripalimab in head and neck squamous cell carcinoma, achieving a confirmed partial response in a heavily pretreated PD-1 refractory patient.

The FDA has not issued an action letter for toripalimab's Biologics License Application by the December 23, 2022 PDUFA date, pending required manufacturing facility inspection in China.